Payment overview · 2025
General Payments
$164.02
7 reported records · 7 companies
Healthcare provider profile · identity verified
Lindsay A Michaelson, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DAYTON, WA · NPI 1093282022
Verified facts
What the public records show
CMS Open Payments records show Lindsay A Michaelson, ARNP received $164.02 in general payments during 2025 across 7 reported records.
Exact Sciences Corporation accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.93 | 18.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.91 | 18.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.49 | 15.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.60 | 13.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.07 | 13.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.31 | 10.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.71 | 10.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $164.02 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $29.93 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.91 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $25.49 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 195 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 162 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 140 | 32 |
| Gabapentin | Gabapentin | 135 | 33 |
| Omeprazole | Omeprazole | 127 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 111 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 88 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 31 |
| Potassium Chloride | Potassium Chloride | 75 | 21 |
| Buspirone Hcl | Buspirone Hcl | 63 | 14 |
| Trazodone Hcl | Trazodone Hcl | 62 | 17 |
| Simvastatin | Simvastatin | 61 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 57 | 18 |
| Losartan Potassium | Losartan Potassium | 54 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 53 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 51 | 13 |
| Famotidine | Famotidine | 50 | 11 |
| Furosemide | Furosemide | 48 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | 11 |
| Sertraline Hcl | Sertraline Hcl | 43 | 13 |
| Allopurinol | Allopurinol | 40 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Naproxen | Naproxen | 37 | suppressed |
| Metformin Hcl | Metformin Hcl | 36 | 15 |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Olanzapine | Olanzapine | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Eliquis | Apixaban | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 22 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Prednisone | Prednisone | 13 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Glipizide | Glipizide | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $164.02 · 7 records | Exact Sciences Corporation | CAPVAXIVE, ELIQUIS, GVOKE HYPOPEN, Kerendia, MOUNJARO, NURTEC ODT, The Cologuard Plus Collection Kit, VOQUEZNA, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error